Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end Significant intellectual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback